North South Ventures

The firm’s website lists four team members—David Naylor, Ilse Treurnicht, Paul Kudlow, and Andrew Lee—without specifying titles or delineating a formal investment committee. Deal review operates on a fixed 14-day cycle, and the team’s unified track record of 800-plus investments suggests a collaborative, partner-level decision process rather than a delegated junior team.

North South Ventures only reviews healthcare companies. The firm requires that a startup show potential to improve patient outcomes, enhance healthcare delivery, or reduce administrative burdens within the sector. Submissions outside of healthcare are not considered, and the firm recommends using DocSend or Google Drive for pitch materials.

No. The firm’s stated policy is to review only healthcare-related startups. Companies that do not fit this mandate receive no response, and the firm explicitly asks founders in other sectors not to submit.

Deal flow arrives primarily through a direct submission channel on the firm’s website, supplemented by email. North South Ventures reviews startups every 14 days and commits to a one-business-day response time for general inquiries. It does not publicize a scout network, institutional LP referral program, or partner-led thematic sourcing program.

The firm covers seed, start-up, and growth-stage healthcare companies. Its portfolio spans early-stage therapeutics, medical devices, and digital health platforms, without publicly distinguishing between pre-seed, Series A, or crossover allocations.

The firm states its team has collectively invested in over 800 companies, producing 23 unicorns, more than 100 FDA approvals across biotech, medical devices, and digital health/AI, and 5 NASDAQ or NYSE IPOs. Those portfolio companies have raised over $10 billion in aggregate funding, according to the firm’s own disclosures.

Its only listed address is 2443 Fillmore Street in San Francisco, California. There are no additional offices disclosed on its website or in available public filings.